You will be able to find all of our recent and archived news announcements. Our press releases are intended for business journalists and analysts/investors.
GSK, Fondazione Telethon and Ospedale San Raffaele announce publication of pivotal safety and efficacy of gene therapy for children with ADA-SCID
GSK today announced the publication in BLOOD of the long-term safety and efficacy data from an analysis of 18 children with ADA-SCID
Salford Lung Study results show COPD patients treated with Relvar® Ellipta® achieve superior reduction in exacerbations compared with ‘usual care’
Pioneering GSK study provides important new data on the effectiveness of Relvar Ellipta (FF/VI) when used in everyday clinical practice.
GSK presents new data at the American Thoracic Society Conference from two pre-specified analyses from the Study to Understand Mortality and MorbidITy (SUMMIT) trial
GSK presents efficacy data for Anoro® Ellipta® in COPD patients who remained symptomatic on tiotropium
GSK and Innoviva, Inc. announce results from data presented at the American Thoracic Society 2016 conference investigating the efficacy and safety of Anoro® Ellipta®
GSK’s Bexsero®▼achieves primary and secondary endpoints with reduced 3-dose schedule (2+1) in safety and immunogenicity study in infants and children
GSK today presented new data for its meningococcal group B vaccine, Bexsero®,1 [Meningococcal group B Vaccine (rDNA, component, adsorbed)] comparing safety and immunogenicity with different dosing schedules in infants and young children, at the annual meeting of the European Society for Paediatric Infectious Diseases (ESPID).
European agency endorses antiseptic gel, developed through GSK and Save the Children partnership, for newborn umbilical cord infections in developing countries
Major milestone for the GSK and Save the Children partnership and its mission to help save the lives of children in the world’s poorest communities
GSK delivers strong Q1 performance with sales of £6.2 billion (+8% CER), core EPS 19.8p (+8% CER); dividend of 19p
2016 core EPS percentage growth now expected to be 10-12% CER
For many years we have been working hard, in partnership with others, to develop vaccines against infectious diseases and to get them to those that need them. This is making a difference.